Eli Lilly Completes Phase 3 Study on Orforglipron for Obesity Treatment

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.

Eli Lilly and Company recently completed a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease.’ The study aimed to evaluate the effectiveness and safety of orforglipron, a new oral medication, in treating obesity-related health issues.

The intervention tested was orforglipron, an oral drug designed to help manage obesity. Participants received varying doses of orforglipron or a placebo to assess its impact.

The study was interventional, with participants randomly assigned to different groups. It followed a parallel model, meaning different groups received different treatments simultaneously. The study was double-blind, ensuring neither participants nor investigators knew who received the actual drug or placebo, focusing primarily on treatment outcomes.

The study began on July 31, 2023, and was completed by August 11, 2025. These dates are crucial as they mark the timeline for data collection and analysis, with the last update submitted in August 2025.

This update could influence Eli Lilly’s stock performance positively, as successful results may enhance investor confidence in the company’s obesity treatment portfolio. It also positions Eli Lilly competitively in the obesity treatment market, potentially impacting other companies in the industry.

The study is completed, with further details available on the ClinicalTrials portal.